nodes	percent_of_prediction	percent_of_DWPC	metapath
Duloxetine—White blood cell count increased—Metformin—polycystic ovary syndrome	0.0352	0.0821	CcSEcCtD
Duloxetine—Seasonal allergy—Metformin—polycystic ovary syndrome	0.0337	0.0786	CcSEcCtD
Duloxetine—Rhinitis seasonal—Metformin—polycystic ovary syndrome	0.0323	0.0755	CcSEcCtD
Duloxetine—Viral diarrhoea—Metformin—polycystic ovary syndrome	0.0271	0.0631	CcSEcCtD
Duloxetine—Epigastric discomfort—Metformin—polycystic ovary syndrome	0.0134	0.0313	CcSEcCtD
Duloxetine—Loose stools—Metformin—polycystic ovary syndrome	0.0128	0.0298	CcSEcCtD
Duloxetine—Upset stomach—Metformin—polycystic ovary syndrome	0.0108	0.0251	CcSEcCtD
Duloxetine—NPY1R—adrenal cortex—polycystic ovary syndrome	0.00943	0.111	CbGeAlD
Duloxetine—CYP1A2—urine—polycystic ovary syndrome	0.00928	0.109	CbGeAlD
Duloxetine—Rigors—Metformin—polycystic ovary syndrome	0.00865	0.0202	CcSEcCtD
Duloxetine—Blood disorder—Metformin—polycystic ovary syndrome	0.00845	0.0197	CcSEcCtD
Duloxetine—Contusion—Metformin—polycystic ovary syndrome	0.00809	0.0189	CcSEcCtD
Duloxetine—NPY1R—pituitary gland—polycystic ovary syndrome	0.00762	0.0896	CbGeAlD
Duloxetine—NPY1R—adipose tissue—polycystic ovary syndrome	0.00758	0.0893	CbGeAlD
Duloxetine—HTR2A—urine—polycystic ovary syndrome	0.00726	0.0854	CbGeAlD
Duloxetine—NPY1R—adrenal gland—polycystic ovary syndrome	0.0068	0.0801	CbGeAlD
Duloxetine—CYP2D6—urine—polycystic ovary syndrome	0.00661	0.0778	CbGeAlD
Duloxetine—NPY1R—vagina—polycystic ovary syndrome	0.00631	0.0742	CbGeAlD
Duloxetine—Naphazoline—ADRA1A—polycystic ovary syndrome	0.00602	0.5	CrCbGaD
Duloxetine—Ear pain—Metformin—polycystic ovary syndrome	0.00601	0.014	CcSEcCtD
Duloxetine—NPY1R—endocrine gland—polycystic ovary syndrome	0.0059	0.0694	CbGeAlD
Duloxetine—Renal impairment—Metformin—polycystic ovary syndrome	0.00539	0.0126	CcSEcCtD
Duloxetine—Hypoglycaemia—Metformin—polycystic ovary syndrome	0.00525	0.0123	CcSEcCtD
Duloxetine—Lethargy—Metformin—polycystic ovary syndrome	0.00523	0.0122	CcSEcCtD
Duloxetine—Pain in extremity—Metformin—polycystic ovary syndrome	0.00513	0.012	CcSEcCtD
Duloxetine—Migraine—Metformin—polycystic ovary syndrome	0.00505	0.0118	CcSEcCtD
Duloxetine—Dehydration—Metformin—polycystic ovary syndrome	0.00477	0.0111	CcSEcCtD
Duloxetine—Liver function test abnormal—Metformin—polycystic ovary syndrome	0.00473	0.011	CcSEcCtD
Duloxetine—Abdominal pain upper—Metformin—polycystic ovary syndrome	0.00468	0.0109	CcSEcCtD
Duloxetine—Breast disorder—Metformin—polycystic ovary syndrome	0.00463	0.0108	CcSEcCtD
Duloxetine—Cramp muscle—Metformin—polycystic ovary syndrome	0.00462	0.0108	CcSEcCtD
Duloxetine—Nasopharyngitis—Metformin—polycystic ovary syndrome	0.00458	0.0107	CcSEcCtD
Duloxetine—Influenza—Metformin—polycystic ovary syndrome	0.00443	0.0103	CcSEcCtD
Duloxetine—Pancreatitis—Metformin—polycystic ovary syndrome	0.00434	0.0101	CcSEcCtD
Duloxetine—Sweating increased—Metformin—polycystic ovary syndrome	0.00432	0.0101	CcSEcCtD
Duloxetine—Abdominal discomfort—Metformin—polycystic ovary syndrome	0.00425	0.00991	CcSEcCtD
Duloxetine—Upper respiratory tract infection—Metformin—polycystic ovary syndrome	0.00412	0.00961	CcSEcCtD
Duloxetine—Infestation—Metformin—polycystic ovary syndrome	0.00395	0.00922	CcSEcCtD
Duloxetine—Infestation NOS—Metformin—polycystic ovary syndrome	0.00395	0.00922	CcSEcCtD
Duloxetine—Hepatobiliary disease—Metformin—polycystic ovary syndrome	0.00374	0.00872	CcSEcCtD
Duloxetine—Hepatitis—Metformin—polycystic ovary syndrome	0.00355	0.00827	CcSEcCtD
Duloxetine—Propranolol—ADRB3—polycystic ovary syndrome	0.00353	0.293	CrCbGaD
Duloxetine—Hypoaesthesia—Metformin—polycystic ovary syndrome	0.00353	0.00823	CcSEcCtD
Duloxetine—Oedema peripheral—Metformin—polycystic ovary syndrome	0.00349	0.00815	CcSEcCtD
Duloxetine—Connective tissue disorder—Metformin—polycystic ovary syndrome	0.00348	0.00813	CcSEcCtD
Duloxetine—Eye disorder—Metformin—polycystic ovary syndrome	0.00331	0.00773	CcSEcCtD
Duloxetine—Flushing—Metformin—polycystic ovary syndrome	0.00329	0.00768	CcSEcCtD
Duloxetine—Cardiac disorder—Metformin—polycystic ovary syndrome	0.00329	0.00768	CcSEcCtD
Duloxetine—Angiopathy—Metformin—polycystic ovary syndrome	0.00322	0.00751	CcSEcCtD
Duloxetine—Immune system disorder—Metformin—polycystic ovary syndrome	0.0032	0.00747	CcSEcCtD
Duloxetine—Mediastinal disorder—Metformin—polycystic ovary syndrome	0.0032	0.00746	CcSEcCtD
Duloxetine—Chills—Metformin—polycystic ovary syndrome	0.00318	0.00742	CcSEcCtD
Duloxetine—Erythema—Metformin—polycystic ovary syndrome	0.00309	0.0072	CcSEcCtD
Duloxetine—Malnutrition—Metformin—polycystic ovary syndrome	0.00309	0.0072	CcSEcCtD
Duloxetine—Flatulence—Metformin—polycystic ovary syndrome	0.00304	0.0071	CcSEcCtD
Duloxetine—Dysgeusia—Metformin—polycystic ovary syndrome	0.00302	0.00705	CcSEcCtD
Duloxetine—Muscle spasms—Metformin—polycystic ovary syndrome	0.00297	0.00693	CcSEcCtD
Duloxetine—Vision blurred—Metformin—polycystic ovary syndrome	0.00291	0.00679	CcSEcCtD
Duloxetine—Tremor—Metformin—polycystic ovary syndrome	0.00289	0.00675	CcSEcCtD
Duloxetine—Ill-defined disorder—Metformin—polycystic ovary syndrome	0.00286	0.00668	CcSEcCtD
Duloxetine—Malaise—Metformin—polycystic ovary syndrome	0.00278	0.0065	CcSEcCtD
Duloxetine—Syncope—Metformin—polycystic ovary syndrome	0.00277	0.00646	CcSEcCtD
Duloxetine—Palpitations—Metformin—polycystic ovary syndrome	0.00273	0.00637	CcSEcCtD
Duloxetine—Loss of consciousness—Metformin—polycystic ovary syndrome	0.00271	0.00633	CcSEcCtD
Duloxetine—Hypertension—Metformin—polycystic ovary syndrome	0.00267	0.00622	CcSEcCtD
Duloxetine—Chest pain—Metformin—polycystic ovary syndrome	0.00263	0.00613	CcSEcCtD
Duloxetine—Myalgia—Metformin—polycystic ovary syndrome	0.00263	0.00613	CcSEcCtD
Duloxetine—Unspecified disorder of skin and subcutaneous tissue—Metformin—polycystic ovary syndrome	0.00261	0.00609	CcSEcCtD
Duloxetine—Discomfort—Metformin—polycystic ovary syndrome	0.0026	0.00606	CcSEcCtD
Duloxetine—Oedema—Metformin—polycystic ovary syndrome	0.00252	0.00588	CcSEcCtD
Duloxetine—Infection—Metformin—polycystic ovary syndrome	0.0025	0.00584	CcSEcCtD
Duloxetine—Shock—Metformin—polycystic ovary syndrome	0.00248	0.00578	CcSEcCtD
Duloxetine—Nervous system disorder—Metformin—polycystic ovary syndrome	0.00247	0.00577	CcSEcCtD
Duloxetine—Thrombocytopenia—Metformin—polycystic ovary syndrome	0.00247	0.00576	CcSEcCtD
Duloxetine—Skin disorder—Metformin—polycystic ovary syndrome	0.00245	0.00571	CcSEcCtD
Duloxetine—Hyperhidrosis—Metformin—polycystic ovary syndrome	0.00244	0.00568	CcSEcCtD
Duloxetine—Anorexia—Metformin—polycystic ovary syndrome	0.0024	0.0056	CcSEcCtD
Duloxetine—HTR2A—embryo—polycystic ovary syndrome	0.00235	0.0276	CbGeAlD
Duloxetine—SLC6A2—adrenal gland—polycystic ovary syndrome	0.00231	0.0272	CbGeAlD
Duloxetine—Musculoskeletal discomfort—Metformin—polycystic ovary syndrome	0.0023	0.00536	CcSEcCtD
Duloxetine—SLC6A4—endocrine gland—polycystic ovary syndrome	0.00227	0.0268	CbGeAlD
Duloxetine—Paraesthesia—Metformin—polycystic ovary syndrome	0.00226	0.00528	CcSEcCtD
Duloxetine—Somnolence—Metformin—polycystic ovary syndrome	0.00224	0.00523	CcSEcCtD
Duloxetine—Dyspepsia—Metformin—polycystic ovary syndrome	0.00222	0.00517	CcSEcCtD
Duloxetine—Decreased appetite—Metformin—polycystic ovary syndrome	0.00219	0.00511	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Metformin—polycystic ovary syndrome	0.00217	0.00508	CcSEcCtD
Duloxetine—Fatigue—Metformin—polycystic ovary syndrome	0.00217	0.00507	CcSEcCtD
Duloxetine—Constipation—Metformin—polycystic ovary syndrome	0.00215	0.00503	CcSEcCtD
Duloxetine—Feeling abnormal—Metformin—polycystic ovary syndrome	0.00208	0.00484	CcSEcCtD
Duloxetine—Gastrointestinal pain—Metformin—polycystic ovary syndrome	0.00206	0.00481	CcSEcCtD
Duloxetine—SLC6A2—endocrine gland—polycystic ovary syndrome	0.002	0.0236	CbGeAlD
Duloxetine—Urticaria—Metformin—polycystic ovary syndrome	0.002	0.00467	CcSEcCtD
Duloxetine—Abdominal pain—Metformin—polycystic ovary syndrome	0.00199	0.00465	CcSEcCtD
Duloxetine—Asthenia—Metformin—polycystic ovary syndrome	0.00181	0.00422	CcSEcCtD
Duloxetine—Pruritus—Metformin—polycystic ovary syndrome	0.00178	0.00416	CcSEcCtD
Duloxetine—Diarrhoea—Metformin—polycystic ovary syndrome	0.00172	0.00402	CcSEcCtD
Duloxetine—Dizziness—Metformin—polycystic ovary syndrome	0.00167	0.00389	CcSEcCtD
Duloxetine—Vomiting—Metformin—polycystic ovary syndrome	0.0016	0.00374	CcSEcCtD
Duloxetine—Rash—Metformin—polycystic ovary syndrome	0.00159	0.00371	CcSEcCtD
Duloxetine—Dermatitis—Metformin—polycystic ovary syndrome	0.00159	0.0037	CcSEcCtD
Duloxetine—Headache—Metformin—polycystic ovary syndrome	0.00158	0.00368	CcSEcCtD
Duloxetine—HTR2A—pituitary gland—polycystic ovary syndrome	0.00155	0.0183	CbGeAlD
Duloxetine—CYP1A2—endocrine gland—polycystic ovary syndrome	0.00154	0.0181	CbGeAlD
Duloxetine—Nausea—Metformin—polycystic ovary syndrome	0.0015	0.00349	CcSEcCtD
Duloxetine—HTR2A—adrenal gland—polycystic ovary syndrome	0.00139	0.0163	CbGeAlD
Duloxetine—Propranolol—ADRB2—polycystic ovary syndrome	0.00134	0.111	CrCbGaD
Duloxetine—HTR2A—vagina—polycystic ovary syndrome	0.00129	0.0151	CbGeAlD
Duloxetine—HTR2A—endocrine gland—polycystic ovary syndrome	0.0012	0.0142	CbGeAlD
Duloxetine—CYP2D6—female gonad—polycystic ovary syndrome	0.00118	0.0139	CbGeAlD
Duloxetine—Propranolol—CYP1A1—polycystic ovary syndrome	0.00115	0.0956	CrCbGaD
Duloxetine—CYP2D6—endocrine gland—polycystic ovary syndrome	0.0011	0.0129	CbGeAlD
Duloxetine—HTR2A—SIDS Susceptibility Pathways—VEGFA—polycystic ovary syndrome	0.00014	0.000295	CbGpPWpGaD
Duloxetine—CYP1A2—Biological oxidations—CYP1A1—polycystic ovary syndrome	0.000139	0.000292	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—FST—polycystic ovary syndrome	0.000138	0.000291	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—ADRA1B—polycystic ovary syndrome	0.000138	0.000291	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—ADRB2—polycystic ovary syndrome	0.000137	0.00029	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—SCT—polycystic ovary syndrome	0.000137	0.000289	CbGpPWpGaD
Duloxetine—CYP1A2—Metapathway biotransformation—CYP1A1—polycystic ovary syndrome	0.000137	0.000288	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—ADRB3—polycystic ovary syndrome	0.000137	0.000288	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PTGER3—polycystic ovary syndrome	0.000136	0.000286	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—LHCGR—polycystic ovary syndrome	0.000136	0.000286	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—LHB—polycystic ovary syndrome	0.000135	0.000284	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—INHBB—polycystic ovary syndrome	0.000134	0.000283	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—GNRH1—polycystic ovary syndrome	0.000132	0.000278	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—SUOX—polycystic ovary syndrome	0.000132	0.000278	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—LPCAT2—polycystic ovary syndrome	0.000132	0.000278	CbGpPWpGaD
Duloxetine—SLC6A4—Circadian rythm related genes—IL6—polycystic ovary syndrome	0.000131	0.000277	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—MTNR1B—polycystic ovary syndrome	0.000131	0.000275	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—IRS1—polycystic ovary syndrome	0.00013	0.000273	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—AKR1C1—polycystic ovary syndrome	0.000128	0.000269	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—HSD3B1—polycystic ovary syndrome	0.000128	0.000269	CbGpPWpGaD
Duloxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—POMC—polycystic ovary syndrome	0.000128	0.000269	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—GNAS—polycystic ovary syndrome	0.000127	0.000269	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PTAFR—polycystic ovary syndrome	0.000127	0.000267	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—SCT—polycystic ovary syndrome	0.000126	0.000267	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PDE3B—polycystic ovary syndrome	0.000125	0.000264	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—ADRB2—polycystic ovary syndrome	0.000125	0.000263	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—POMC—polycystic ovary syndrome	0.000125	0.000263	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—INS—polycystic ovary syndrome	0.000124	0.000262	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—ADRA1D—polycystic ovary syndrome	0.000123	0.000259	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—ISYNA1—polycystic ovary syndrome	0.000122	0.000258	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—GHRL—polycystic ovary syndrome	0.000122	0.000258	CbGpPWpGaD
Duloxetine—CYP2D6—Biological oxidations—POMC—polycystic ovary syndrome	0.000122	0.000257	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—NMNAT3—polycystic ovary syndrome	0.000122	0.000257	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—MTNR1B—polycystic ovary syndrome	0.000121	0.000254	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—IGF1—polycystic ovary syndrome	0.00012	0.000253	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—AKT2—polycystic ovary syndrome	0.00012	0.000253	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—ADRA1B—polycystic ovary syndrome	0.00012	0.000252	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—FGF18—polycystic ovary syndrome	0.000119	0.00025	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—RBP4—polycystic ovary syndrome	0.000118	0.000248	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—INHBB—polycystic ovary syndrome	0.000117	0.000246	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—LHB—polycystic ovary syndrome	0.000116	0.000245	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—GNAS—polycystic ovary syndrome	0.000116	0.000244	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—FSHR—polycystic ovary syndrome	0.000114	0.000241	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—SERPINE1—polycystic ovary syndrome	0.000114	0.00024	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—HSD3B2—polycystic ovary syndrome	0.000114	0.00024	CbGpPWpGaD
Duloxetine—HTR2C—GPCR ligand binding—POMC—polycystic ovary syndrome	0.000112	0.000236	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—LPCAT2—polycystic ovary syndrome	0.000112	0.000235	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—SUOX—polycystic ovary syndrome	0.000112	0.000235	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—GHRL—polycystic ovary syndrome	0.000111	0.000234	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—AKR1C1—polycystic ovary syndrome	0.00011	0.000232	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—YAP1—polycystic ovary syndrome	0.00011	0.000231	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PDE3B—polycystic ovary syndrome	0.000109	0.00023	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—GAB1—polycystic ovary syndrome	0.000108	0.000228	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—RACGAP1—polycystic ovary syndrome	0.000107	0.000226	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—GHRL—polycystic ovary syndrome	0.000106	0.000224	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—ADRA1A—polycystic ovary syndrome	0.000104	0.00022	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—AKR1C2—polycystic ovary syndrome	0.000104	0.000219	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—TEAD2—polycystic ovary syndrome	0.000104	0.000219	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—ISYNA1—polycystic ovary syndrome	0.000104	0.000219	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—INSR—polycystic ovary syndrome	0.000103	0.000218	CbGpPWpGaD
Duloxetine—CYP1A2—Biological oxidations—POMC—polycystic ovary syndrome	0.000103	0.000218	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—FST—polycystic ovary syndrome	0.000102	0.000215	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—SULT2A1—polycystic ovary syndrome	0.000101	0.000214	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—ADRB2—polycystic ovary syndrome	0.000101	0.000213	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—ADRB3—polycystic ovary syndrome	0.000101	0.000212	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—LHB—polycystic ovary syndrome	9.94e-05	0.000209	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—FSHR—polycystic ovary syndrome	9.92e-05	0.000209	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—AKR1C3—polycystic ovary syndrome	9.83e-05	0.000207	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—GNRH1—polycystic ovary syndrome	9.71e-05	0.000205	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—POMC—polycystic ovary syndrome	9.71e-05	0.000205	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—TNRC6B—polycystic ovary syndrome	9.68e-05	0.000204	CbGpPWpGaD
Duloxetine—HTR2A—SIDS Susceptibility Pathways—IL6—polycystic ovary syndrome	9.67e-05	0.000204	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—GHRL—polycystic ovary syndrome	9.64e-05	0.000203	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—PGR—polycystic ovary syndrome	9.58e-05	0.000202	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—YAP1—polycystic ovary syndrome	9.46e-05	0.000199	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—AKR1C1—polycystic ovary syndrome	9.41e-05	0.000198	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—GNAS—polycystic ovary syndrome	9.39e-05	0.000198	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—RACGAP1—polycystic ovary syndrome	9.33e-05	0.000197	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—SCT—polycystic ovary syndrome	9.31e-05	0.000196	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—ADRB2—polycystic ovary syndrome	9.19e-05	0.000194	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—IL6—polycystic ovary syndrome	9.18e-05	0.000194	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—ADRA1A—polycystic ovary syndrome	9.07e-05	0.000191	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—CYP11A1—polycystic ovary syndrome	8.98e-05	0.000189	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—PLAT—polycystic ovary syndrome	8.91e-05	0.000188	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—GHRL—polycystic ovary syndrome	8.91e-05	0.000188	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—MTNR1B—polycystic ovary syndrome	8.88e-05	0.000187	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—FST—polycystic ovary syndrome	8.84e-05	0.000186	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—TEAD2—polycystic ovary syndrome	8.82e-05	0.000186	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—AKR1C2—polycystic ovary syndrome	8.82e-05	0.000186	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—ADRB2—polycystic ovary syndrome	8.79e-05	0.000185	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—ADRB3—polycystic ovary syndrome	8.73e-05	0.000184	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—FGF18—polycystic ovary syndrome	8.73e-05	0.000184	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PNPLA2—polycystic ovary syndrome	8.72e-05	0.000184	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—RBP4—polycystic ovary syndrome	8.66e-05	0.000182	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—LHB—polycystic ovary syndrome	8.63e-05	0.000182	CbGpPWpGaD
Duloxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—polycystic ovary syndrome	8.62e-05	0.000182	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—POMC—polycystic ovary syndrome	8.58e-05	0.000181	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—GNAS—polycystic ovary syndrome	8.52e-05	0.00018	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—ATF1—polycystic ovary syndrome	8.5e-05	0.000179	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—AKR1C3—polycystic ovary syndrome	8.48e-05	0.000179	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—GNRH1—polycystic ovary syndrome	8.43e-05	0.000178	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—CYP17A1—polycystic ovary syndrome	8.35e-05	0.000176	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—TCF7L2—polycystic ovary syndrome	8.29e-05	0.000175	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—SRD5A1—polycystic ovary syndrome	8.27e-05	0.000174	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—AKT2—polycystic ovary syndrome	8.25e-05	0.000174	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—AKR1C1—polycystic ovary syndrome	8.17e-05	0.000172	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—GNAS—polycystic ovary syndrome	8.15e-05	0.000172	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—SCT—polycystic ovary syndrome	8.09e-05	0.00017	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—YAP1—polycystic ovary syndrome	8.08e-05	0.00017	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—ADRB2—polycystic ovary syndrome	7.98e-05	0.000168	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—GAB1—polycystic ovary syndrome	7.97e-05	0.000168	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—STAR—polycystic ovary syndrome	7.89e-05	0.000166	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—NGFR—polycystic ovary syndrome	7.84e-05	0.000165	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—VEGFA—polycystic ovary syndrome	7.84e-05	0.000165	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—POMC—polycystic ovary syndrome	7.79e-05	0.000164	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—PRL—polycystic ovary syndrome	7.77e-05	0.000164	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—MTNR1B—polycystic ovary syndrome	7.71e-05	0.000163	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—INSR—polycystic ovary syndrome	7.62e-05	0.000161	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—FGF18—polycystic ovary syndrome	7.58e-05	0.00016	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—RBP4—polycystic ovary syndrome	7.52e-05	0.000158	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—AKT2—polycystic ovary syndrome	7.49e-05	0.000158	CbGpPWpGaD
Duloxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—polycystic ovary syndrome	7.48e-05	0.000158	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—GNAS—polycystic ovary syndrome	7.4e-05	0.000156	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PNPLA2—polycystic ovary syndrome	7.39e-05	0.000156	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—ADRB2—polycystic ovary syndrome	7.37e-05	0.000155	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—AKR1C3—polycystic ovary syndrome	7.24e-05	0.000153	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—TNRC6B—polycystic ovary syndrome	7.13e-05	0.00015	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PGR—polycystic ovary syndrome	7.06e-05	0.000149	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—HMMR—polycystic ovary syndrome	7.03e-05	0.000148	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—YAP1—polycystic ovary syndrome	7.02e-05	0.000148	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—SRD5A1—polycystic ovary syndrome	7.01e-05	0.000148	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—GAB1—polycystic ovary syndrome	6.92e-05	0.000146	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—GNAS—polycystic ovary syndrome	6.84e-05	0.000144	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—HSD3B1—polycystic ovary syndrome	6.71e-05	0.000141	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—STAR—polycystic ovary syndrome	6.68e-05	0.000141	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—INSR—polycystic ovary syndrome	6.62e-05	0.000139	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—CYP19A1—polycystic ovary syndrome	6.61e-05	0.000139	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PLAT—polycystic ovary syndrome	6.56e-05	0.000138	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—GHRL—polycystic ovary syndrome	6.56e-05	0.000138	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—NCOR1—polycystic ovary syndrome	6.51e-05	0.000137	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—NRG1—polycystic ovary syndrome	6.39e-05	0.000135	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—POMC—polycystic ovary syndrome	6.32e-05	0.000133	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—AKR1C3—polycystic ovary syndrome	6.29e-05	0.000133	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—ATF1—polycystic ovary syndrome	6.26e-05	0.000132	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—TNRC6B—polycystic ovary syndrome	6.19e-05	0.00013	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PGR—polycystic ovary syndrome	6.13e-05	0.000129	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—LHB—polycystic ovary syndrome	6.12e-05	0.000129	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—TCF7L2—polycystic ovary syndrome	6.1e-05	0.000129	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—AKT2—polycystic ovary syndrome	6.08e-05	0.000128	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—HSD3B2—polycystic ovary syndrome	5.98e-05	0.000126	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—HMMR—polycystic ovary syndrome	5.96e-05	0.000126	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—AKR1C1—polycystic ovary syndrome	5.79e-05	0.000122	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—NGFR—polycystic ovary syndrome	5.78e-05	0.000122	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—POMC—polycystic ovary syndrome	5.74e-05	0.000121	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PRL—polycystic ovary syndrome	5.72e-05	0.000121	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PLAT—polycystic ovary syndrome	5.7e-05	0.00012	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—GHRL—polycystic ovary syndrome	5.7e-05	0.00012	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—HSD3B1—polycystic ovary syndrome	5.68e-05	0.00012	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—NCOR1—polycystic ovary syndrome	5.62e-05	0.000118	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—AKT2—polycystic ovary syndrome	5.52e-05	0.000116	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—POMC—polycystic ovary syndrome	5.49e-05	0.000116	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—IRS2—polycystic ovary syndrome	5.48e-05	0.000115	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—ATF1—polycystic ovary syndrome	5.43e-05	0.000115	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—ADRB2—polycystic ovary syndrome	5.43e-05	0.000114	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—IL6—polycystic ovary syndrome	5.42e-05	0.000114	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—LEP—polycystic ovary syndrome	5.36e-05	0.000113	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—SULT2A1—polycystic ovary syndrome	5.33e-05	0.000112	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—polycystic ovary syndrome	5.33e-05	0.000112	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—TCF7L2—polycystic ovary syndrome	5.3e-05	0.000112	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—AKT2—polycystic ovary syndrome	5.28e-05	0.000111	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—LHB—polycystic ovary syndrome	5.18e-05	0.000109	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—RRM2—polycystic ovary syndrome	5.16e-05	0.000109	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—HSD3B2—polycystic ovary syndrome	5.07e-05	0.000107	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—GNAS—polycystic ovary syndrome	5.04e-05	0.000106	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—NGFR—polycystic ovary syndrome	5.02e-05	0.000106	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—POMC—polycystic ovary syndrome	4.98e-05	0.000105	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—YAP1—polycystic ovary syndrome	4.98e-05	0.000105	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PRL—polycystic ovary syndrome	4.97e-05	0.000105	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—AKR1C1—polycystic ovary syndrome	4.91e-05	0.000103	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—NCOR1—polycystic ovary syndrome	4.8e-05	0.000101	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—AKT2—polycystic ovary syndrome	4.79e-05	0.000101	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—IRS1—polycystic ovary syndrome	4.78e-05	0.000101	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—NAMPT—polycystic ovary syndrome	4.78e-05	0.000101	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CYP11A1—polycystic ovary syndrome	4.72e-05	9.95e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—ADRB2—polycystic ovary syndrome	4.72e-05	9.94e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—NRG1—polycystic ovary syndrome	4.71e-05	9.92e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—POMC—polycystic ovary syndrome	4.6e-05	9.7e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—INS—polycystic ovary syndrome	4.58e-05	9.65e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—SULT2A1—polycystic ovary syndrome	4.52e-05	9.52e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—AKR1C3—polycystic ovary syndrome	4.46e-05	9.4e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—IGF1—polycystic ovary syndrome	4.43e-05	9.33e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—AKT2—polycystic ovary syndrome	4.43e-05	9.33e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CYP17A1—polycystic ovary syndrome	4.39e-05	9.25e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—RRM2—polycystic ovary syndrome	4.37e-05	9.22e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—GNAS—polycystic ovary syndrome	4.37e-05	9.22e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—YAP1—polycystic ovary syndrome	4.22e-05	8.88e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—SERPINE1—polycystic ovary syndrome	4.21e-05	8.86e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—NCOR1—polycystic ovary syndrome	4.17e-05	8.78e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—NRG1—polycystic ovary syndrome	4.09e-05	8.62e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—NAMPT—polycystic ovary syndrome	4.05e-05	8.54e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—IRS2—polycystic ovary syndrome	4.03e-05	8.5e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—polycystic ovary syndrome	4.03e-05	8.49e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CYP11A1—polycystic ovary syndrome	4e-05	8.43e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—POMC—polycystic ovary syndrome	3.97e-05	8.37e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—LEP—polycystic ovary syndrome	3.95e-05	8.32e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—TH—polycystic ovary syndrome	3.8e-05	8e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—AKR1C3—polycystic ovary syndrome	3.78e-05	7.96e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CYP17A1—polycystic ovary syndrome	3.72e-05	7.84e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—SLC2A4—polycystic ovary syndrome	3.69e-05	7.79e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—IRS1—polycystic ovary syndrome	3.52e-05	7.42e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—IRS2—polycystic ovary syndrome	3.5e-05	7.38e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CYP19A1—polycystic ovary syndrome	3.47e-05	7.32e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—LEP—polycystic ovary syndrome	3.43e-05	7.22e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—POMC—polycystic ovary syndrome	3.39e-05	7.15e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—IL6—polycystic ovary syndrome	3.39e-05	7.14e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—INS—polycystic ovary syndrome	3.37e-05	7.11e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—IGF1—polycystic ovary syndrome	3.26e-05	6.87e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—AKT2—polycystic ovary syndrome	3.26e-05	6.87e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—TH—polycystic ovary syndrome	3.22e-05	6.78e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—SLC2A4—polycystic ovary syndrome	3.13e-05	6.6e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—GNAS—polycystic ovary syndrome	3.1e-05	6.53e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—SERPINE1—polycystic ovary syndrome	3.1e-05	6.53e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—IRS1—polycystic ovary syndrome	3.06e-05	6.44e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—NCOR1—polycystic ovary syndrome	2.95e-05	6.22e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—POMC—polycystic ovary syndrome	2.94e-05	6.21e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CYP19A1—polycystic ovary syndrome	2.94e-05	6.2e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—INS—polycystic ovary syndrome	2.93e-05	6.17e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.89e-05	6.1e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—IGF1—polycystic ovary syndrome	2.83e-05	5.97e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—AKT2—polycystic ovary syndrome	2.83e-05	5.96e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CYP1A1—polycystic ovary syndrome	2.8e-05	5.9e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.69e-05	5.67e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GNAS—polycystic ovary syndrome	2.63e-05	5.54e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—MTHFR—polycystic ovary syndrome	2.61e-05	5.5e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—NCOR1—polycystic ovary syndrome	2.5e-05	5.27e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—IL6—polycystic ovary syndrome	2.49e-05	5.26e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CYP1A1—polycystic ovary syndrome	2.37e-05	5e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—MTHFR—polycystic ovary syndrome	2.21e-05	4.66e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—IL6—polycystic ovary syndrome	2.17e-05	4.56e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.13e-05	4.49e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PPARG—polycystic ovary syndrome	2.12e-05	4.46e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—POMC—polycystic ovary syndrome	2.09e-05	4.4e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—INS—polycystic ovary syndrome	2.08e-05	4.38e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—IL6—polycystic ovary syndrome	2e-05	4.22e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.85e-05	3.9e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PPARG—polycystic ovary syndrome	1.79e-05	3.78e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—POMC—polycystic ovary syndrome	1.77e-05	3.73e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—INS—polycystic ovary syndrome	1.76e-05	3.71e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—IL6—polycystic ovary syndrome	1.47e-05	3.11e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—IL6—polycystic ovary syndrome	1.28e-05	2.7e-05	CbGpPWpGaD
